Sionna Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $181.05M
- P/E (TTM)
- –
- Dividend yield
- –
About Sionna Therapeutics
Pharmaceutical Preparations, SIC 2834
This clinical-stage biopharmaceutical company discovers and develops small-molecule therapeutics to treat cystic fibrosis by restoring CFTR protein function. Its pipeline centers on nucleotide binding domain 1 (NBD1) stabilizers, notably lead candidates SION-719 and SION-451, designed to correct defects caused by the F508del genetic mutation. The company also advances complementary CFTR modulators, including transmembrane domain 1 correctors such as SION-2222 and SION-2851, the intracellular loop 4 corrector SION-109, and the potentiator SION-3067. Its product candidates are designed either to be administered alongside the existing standard of care or paired into proprietary dual-combination therapies. The company targets people living with cystic fibrosis, particularly individuals carrying the F508del mutation.
The company operates as a clinical-stage entity without disclosing commercial offices, physical facilities, or operational territories in the excerpt. Its clinical development activities encompass Phase 1 and Phase 2a clinical trials evaluating healthy adult participants and cystic fibrosis patients. The provided text does not state the location of the company's headquarters.
Summary of the business section of Sionna Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sionna Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 21 Hickory Drive, Suite 500 02451
- Phone
- (617) 819-2020
- Website
- sionnatx.com
- Employees
- 59, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte& Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SION
- Exchange
- Nasdaq
- IPO date
- Feb 7, 2025
- Shares outstanding
- 45M, Jul 31, 2026
- Public float
- $342.01M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2036042
- CUSIP
- 829401108
- ISIN
- US8294011080
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Cloonan | President & CEO, Director | 765,393 |
| Charlotte McKee | CMO and Head of R&D | 78,415 |
| Elena Ridloff | CFO and CBO | 85,801 |
| Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | 28,133 |
| Caroline Stark Beer | Chief Business Officer | – |
| Ra Capital Management, L.P. | Director | 3,448,812 |
| Capital Healthcare Fund LP RA | Director | – |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | 715,988 |
| Peter Kolchinsky | Director | 2,198,082 |
| RA Capital Nexus Fund, L.P. | Director | – |
| Capital GP VIII LLC OrbiMed | Director | 2,469,959 |
| Peter A. Thompson | Director | 2,469,959 |
| Advisors Llc Orbimed | Director | 2,555,877 |
| Harold Edward Fleming | Director | – |
| Joanne L. Viney | Director | – |
| Marcella K. Ruddy | Director | – |
| Paul J. Clancy | Director | – |
| Bruce Booth | Director | 3,057,453 |
| Laurie Stelzer | Director | – |
| Joshua Resnick | Director | – |
| Lucian Iancovici | Director | – |
Employees
Headcount reported in annual reports
“As of February 15, 2026, we had 59 full-time employees, of which 15 had M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 7, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 4, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |